| dc.description.abstract | Background: The increasing incidence of eye tumors is an eye health problem. Currently, immunotherapy is a promising therapeutic option for tumor cases. One of the targets of immunotherapy is Fibrinogen-like protein 1 (FGL-1), which is associated with the prediction of therapeutic effects and the prognosis of tumor therapy.
Objective: The goal of the research is to investigate the association between Fibrinogen-Like Protein 1 (FGL-1) and the incidence of eye tumors at the Universitas Sumatera Utara Hospital, Medan.
Materials and Methods: This research is an analytic observational study with a case-control design. A total of 26 subjects with eye tumors in the study group and 26 subjects without eye tumors in the control group participated in this study. A comparison was made between the study group and the control group to see the relationship between Fibrinogen-Like Protein 1 (FGL-1) and the incidence of eye tumors. FGL-1 secreted in plasma was detected using the Enzyme-Linked Immunoabsorbent Assay method.
Results: In the study of 26 subjects with eye tumors, six were found to have malignant tumors, while the majority of tumors (19 cases) were located in the lids and adnexa. The study found a significant correlation between FGL-1 levels and the prevalence of eye tumors (p <0.001). Furthermore, the investigation discovered an association between FGL-1 levels and the incidence of eye tumors based on both age and gender.
Conclusion: Serum FGL-1 levels were observed and compared in eye tumor patients and controls. The results showed that high FGL-1 levels were found to be significant in most types of eye tumors. In addition, high FGL-1 expression is associated with age, sex, and the type of ocular tumor malignancy. Abnormal expression of FGL-1 in eye tumors may be related to the type of malignancy in eye tumors. So the expression level of FGL-1 can be further correlated with the development of eye tumors and its possible potential as an immunotherapy target in the development of eye tumor therapy. However, further research is needed to examine and understand the possible role of FGL-1 as an immunotherapy target in eye tumors.. | en_US |
